Document is current
Any future updates will be listed below
-
Authors
Aird, Eric J. https://orcid.org/0000-0002-4873-042X
Serrano-Benitez, Almudena https://orcid.org/0000-0002-7263-6863
Siegner, Sebastian M. https://orcid.org/0000-0001-6811-0474
Cannavo, Elda
Belotserkovskaya, Rimma
Gueorguieva, Nadia
Fielden, John
Cullot, Grégoire
Ammann, Sandra https://orcid.org/0000-0003-0385-1890
Bader, Aldo S.
Gupta, Vipul
Andrieux, Geoffroy https://orcid.org/0000-0002-5389-9481
Raab, Rebecca https://orcid.org/0009-0002-4743-057X
Del Rey González, Mónica
Cathomen, Toni https://orcid.org/0000-0002-7757-4630
Cejka, Petr https://orcid.org/0000-0002-9087-032X
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
Jackson, Stephen P. https://orcid.org/0000-0001-9317-7937
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 6 February 2026
First Online: 25 February 2026
Competing interests
: T.Ca. and G.A. are inventors of CAST-Seq patents (e.g., US11319580B2 and EP3856928B1). J.E.C. is a co-founder and SAB member of Serac Biosciences and an SAB member of Relation Therapeutics, Hornet Bio, and Kano Therapeutics. E.J.A. was partly supported by funding from CSL Behring. S.P.J. works part-time at Insmed Innovation UK Ltd. S.P.J. is a founding partner of Ahren Innovation Capital LLP, a co-founder of Mission Therapeutics Ltd, and is a consultant and shareholder of Genome Therapeutics Ltd. The remaining authors declare no competing interests.
